metformin has been researched along with Ache in 14 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism." | 8.31 | [Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023) |
| "Metformin is a well-tolerated antidiabetic drug and has recently been repurposed for numerous diseases, including pain." | 8.12 | Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain. ( Dasuni Wasana, PW; Muangnoi, C; Rojsitthisak, P; Towiwat, P; Vajragupta, O, 2022) |
| "Metformin was administered orally every day to rats with OA." | 5.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "We found consistent evidence across pre-clinical and human studies to support a favourable effect of metformin on chondroprotection, immunomodulation and pain reduction in knee osteoarthritis." | 5.22 | Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies. ( Abidi, J; Cicuttini, FM; Estee, M; Hussain, SM; Lim, YZ; Little, CB; Udaya Kumar, M; Wang, Y; Wluka, AE, 2022) |
| "To observe the therapeutic effect of metformin on pathological pain in mice with radiation dermatitis and explore the underlying mechanism." | 4.31 | [Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway]. ( An, Q; Cao, J; Han, F; Liu, H, 2023) |
| "Metformin is a well-tolerated antidiabetic drug and has recently been repurposed for numerous diseases, including pain." | 4.12 | Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain. ( Dasuni Wasana, PW; Muangnoi, C; Rojsitthisak, P; Towiwat, P; Vajragupta, O, 2022) |
| "Metformin is a hypoglycemic drug widely used in the treatment of type 2 diabetes." | 2.82 | Is metformin a possible treatment for diabetic neuropathy? ( Huang, M; Jia, S; Wang, P; Wei, J; Wei, Y, 2022) |
| "Metformin was administered orally every day to rats with OA." | 1.62 | Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway. ( Cho, KH; Cho, ML; Choi, JW; Jung, K; Kim, SJ; Kwon, JY; Lee, AR; Lee, DH; Lee, SH; Lee, SY; Min, HK; Na, HS; Park, SH; Woo, JS, 2021) |
| "LDH evoked persistent thermal hyperalgesia and mechanical allodynia on the ipsilateral paw, as indicated by the decreased PWL and 50% PWT." | 1.51 | AMP-Activated Protein Kinase Activation in Dorsal Root Ganglion Suppresses mTOR/p70S6K Signaling and Alleviates Painful Radiculopathies in Lumbar Disc Herniation Rat Model. ( Guo, Y; Li, H; Li, J; Li, Z; Liu, Y; Liu, Z; Shang, Y, 2019) |
| "Chronic pain is a common complication of diabetes." | 1.42 | Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. ( Byrne, FM; Chapman, V; Cheetham, S; Vickers, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, YZ | 1 |
| Wang, Y | 1 |
| Estee, M | 1 |
| Abidi, J | 1 |
| Udaya Kumar, M | 1 |
| Hussain, SM | 1 |
| Wluka, AE | 1 |
| Little, CB | 1 |
| Cicuttini, FM | 1 |
| Dasuni Wasana, PW | 1 |
| Muangnoi, C | 1 |
| Vajragupta, O | 1 |
| Rojsitthisak, P | 2 |
| Towiwat, P | 1 |
| Wei, J | 1 |
| Wei, Y | 1 |
| Huang, M | 1 |
| Wang, P | 1 |
| Jia, S | 1 |
| Pușcașu, C | 1 |
| Ungurianu, A | 1 |
| Șeremet, OC | 1 |
| Andrei, C | 1 |
| Mihai, DP | 1 |
| Negreș, S | 1 |
| Cao, J | 1 |
| Liu, H | 1 |
| An, Q | 1 |
| Han, F | 1 |
| Na, HS | 1 |
| Kwon, JY | 1 |
| Lee, SY | 1 |
| Lee, SH | 1 |
| Lee, AR | 1 |
| Woo, JS | 1 |
| Jung, K | 1 |
| Cho, KH | 1 |
| Choi, JW | 1 |
| Lee, DH | 1 |
| Min, HK | 1 |
| Park, SH | 1 |
| Kim, SJ | 1 |
| Cho, ML | 1 |
| Burton, MD | 1 |
| Tillu, DV | 1 |
| Mazhar, K | 1 |
| Mejia, GL | 1 |
| Asiedu, MN | 2 |
| Inyang, K | 1 |
| Hughes, T | 1 |
| Lian, B | 1 |
| Dussor, G | 2 |
| Price, TJ | 2 |
| Liu, Y | 1 |
| Li, J | 1 |
| Li, H | 1 |
| Shang, Y | 1 |
| Guo, Y | 1 |
| Li, Z | 1 |
| Liu, Z | 1 |
| Byrne, FM | 1 |
| Cheetham, S | 1 |
| Vickers, S | 1 |
| Chapman, V | 1 |
| Bullón, P | 1 |
| Alcocer-Gómez, E | 1 |
| Carrión, AM | 1 |
| Marín-Aguilar, F | 1 |
| Garrido-Maraver, J | 1 |
| Román-Malo, L | 1 |
| Ruiz-Cabello, J | 1 |
| Culic, O | 1 |
| Ryffel, B | 1 |
| Apetoh, L | 1 |
| Ghiringhelli, F | 1 |
| Battino, M | 1 |
| Sánchez-Alcazar, JA | 1 |
| Cordero, MD | 1 |
| Tokmak, M | 1 |
| Altiok, IB | 1 |
| Guven, M | 1 |
| Aras, AB | 1 |
| Cosar, M | 1 |
| Han, C | 1 |
| Dib-Hajj, SD | 1 |
| Waxman, SG | 1 |
| Petznick, A | 1 |
| Labuzek, K | 1 |
| Liber, S | 1 |
| Marcol, W | 1 |
| Okopień, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Preventing Injured Knees From osteoArthritis: Severity Outcomes (PIKASO)[NCT06096259] | Phase 2 | 512 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension[NCT02540486] | 139 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Ache
| Article | Year |
|---|---|
Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies.
Topics: Adenosine Monophosphate; Analgesics; Humans; Metformin; Osteoarthritis, Knee; Pain; Protein Kinases | 2022 |
Is metformin a possible treatment for diabetic neuropathy?
Topics: Adenosine Monophosphate; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agen | 2022 |
12 other studies available for metformin and Ache
| Article | Year |
|---|---|
Curcumin and metformin synergistically modulate peripheral and central immune mechanisms of pain.
Topics: Analgesics; Anti-Inflammatory Agents; Curcumin; Humans; Metformin; Pain | 2022 |
The Influence of Sildenafil-Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice.
Topics: Animals; Biomarkers; Diabetes Mellitus; Diabetic Neuropathies; Hyperalgesia; Hypoglycemic Agents; In | 2023 |
[Metformin alleviates pathologic pain in mice with radiation dermatitis by inhibiting p38MAPK/NF-κB signaling pathway].
Topics: Animals; Gabapentin; Interleukin-6; Male; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred | 2023 |
Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy-Lysosomal Pathway.
Topics: Animals; Arthritis, Experimental; Celecoxib; Chondrocytes; Diabetes Mellitus, Type 2; Disease Models | 2021 |
Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming in mice.
Topics: AMP-Activated Protein Kinases; Analgesics; Animals; Cells, Cultured; Ganglia, Spinal; Hyperalgesia; | 2017 |
AMP-Activated Protein Kinase Activation in Dorsal Root Ganglion Suppresses mTOR/p70S6K Signaling and Alleviates Painful Radiculopathies in Lumbar Disc Herniation Rat Model.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Ganglia, Spinal; Hyperalgesia; Inter | 2019 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neu | 2015 |
AMPK Phosphorylation Modulates Pain by Activation of NLRP3 Inflammasome.
Topics: Adult; AMP-Activated Protein Kinases; Animals; Carrier Proteins; Female; Fibromyalgia; Humans; Indol | 2016 |
Spontaneous Regression of Lumbar Disc Herniation After Weight Loss: Case Report.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Intervertebral Disc Displacem | 2015 |
The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development.
Topics: AMP-Activated Protein Kinases; Analgesics; Anesthetics, Local; Animals; Binding Sites; Biphenyl Comp | 2017 |
Insulin management of type 2 diabetes mellitus.
Topics: Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug | 2011 |
Controlling newly diagnosed type 2 diabetes mellitus with metformin managed pain symptoms in a patient affected with Dercum's disease.
Topics: Adiposis Dolorosa; Analgesics; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metform | 2012 |